Cannasat Therapeutics and IntelGenx Enter into a Collaborative Agreement to Develop Novel Drug Delivery Products
"We are excited to work with IntelGenx to develop new cannabinoid pharmaceuticals that could potentially address a wide range of therapeutic indications such as neuropathic pain, where there is currently a large unmet medical need for new therapies. IntelGenx's technology platform complements our existing drug delivery technologies and provides us an opportunity to broaden our growing intellectual property portfolio and product development pipeline. We are committed to expanding our arsenal of drug delivery technologies that can enhance the effectiveness of cannabinoid-based drugs," said David Hill, CEO of Cannasat Therapeutics.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.